FlashMed

Titolo	Mineral and bone disease pattern in elderly haemodialysis patients
Autore	Solenne Pelletier1, Hubert Roth2, Jean-Louis Bouchet3, Tilman Drueke4, Gerard London5, Denis Fouque1,2 and the French Phosphorus and Calcium Observatory investigators* - 1Université Claude Bernard Lyon I, Hospices Civils de Lyon, Department of Nephrology, Lyon, France, 2Centre de Recherche en Nutrition Humaine Rhône-Alpes, Grenoble, France, 3Clinique Saint-Augustin, Bordeaux, France, 4Inserm Unit 845 and Service de Néphrologie, Hôpital Necker, Paris, France and 5Hôpital Manhes, Fleury-Merogis, France
Referenza	Nephrol Dial Transplant (2010); 25: 3062-3070
Contenuto	Background. Although many studies have recently addressed the mineral and bone disorder of chronic kidney disease (CKD-MBD), only limited information is available for elderly dialysis patients. Methods. We prospectively collected serum phosphorus, calcium, parathyroid hormone (PTH), 25(OH) vitamin D, albumin, C-reactive protein, protein intake and CKDMBD treatments in 9169 maintenance haemodialysis patients in France in June 2008. We then compared biological and treatment patterns in 3403 patients aged 75 or over to their younger counterparts. Results. Elderly patients exhibited lower serum phosphorus and parathyroid hormone concentrations (−8 and −18%, respectively) but slightly higher corrected serum calcium levels (+2%) compared to patients aged below 75 years. Elderly patients had higher mean C-reactive protein, lower serum albumin levels and reduced protein intake. Calcium and non-calcium phosphate binders as well as cinacalcet usage and dosage were significantly reduced in elderly patients, with a trend towards lower active vitamin D derivatives usage. Elderly patients were better controlled according to the Kidney Disease Outcome Quality Initiative (K/DOQI) targets compared to patients aged below 75. Conclusion. In this large 2008 cohort of elderly haemodialysis patients, it appears easier to control serum parameters of CKD-MBD as compared to younger dialysis patients. A better control of serum phosphorus was observed, with less phosphate binder and reduced cinacalcet dosage.
Data	03.09.2010

Lista completa